CGGYY yields 4.85% · JNJ yields 2.13%● Live data
📍 JNJ pulled ahead of the other in Year 6
Combined, CGGYY + JNJ cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of CGGYY + JNJ for your $10,000?
Viridien engages in the provision of data, products, services, and solutions in Earth science, data science, sensing, and monitoring in North America, Latin America, the Central and South Americas, Europe, Africa, the Middle East, and the Asia Pacific. It operates through two segments: Data, Digital & Energy Transition (DDE); and Sensing & Monitoring (SMO). The DDE segments engages in the developing and licensing Earth data seismic surveys; processing and imaging seismic data; sale of seismic data processing software under the Geovation brand; provision of geoscience and petroleum engineering consulting services; and collecting, developing, and licensing geological data. The SMO segment is involved in the design, engineering, and manufacturing of seismic equipment for the land and marine seismic data acquisition, including seismic recording equipment, software, and seismic sources for land vibrators or marine sources, and sensing and monitoring equipment and solutions under the Sercel, Metrolog, GRC, DeRegt, and Geocomp brand names. This segment also provides customer support services, such as training. It provides its solutions for natural resources, environmental, infrastructure, energy transition, and digital applications. The company was formerly known as CGG and changed its name to Viridien in May 2024. Viridien was incorporated in 1931 and is headquartered in Massy, France.
Full CGGYY Calculator →Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.
Full JNJ Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.